ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/endometrial/metastatic/mmr-deficient
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gynaecological / Endometrial - Metastatic / MMR deficient
7
trial(s) found.
NCT07262619
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (
MSI
-H) or
Mismatch
Repair
Deficient
(
dMMR
) Tumors (
EIK1005-002
)
WRN inhibitor
anti-PD-1 monoclonal antibody
Cancer
Endometrial cancer
Gastric cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Solid tumour
dMMR solid cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - PASO Medical
NCT06989112
Advanced
Phase 3
Recruiting
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+),
Mismatch
Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer (
DE-01
)
anti-ERBB2 antibody-drug conjugate
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Prince of Wales Hospital
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06952504
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With
Mismatch
Repair Proficient Endometrial Cancer (
TroFuse-033
/GOG-3119/ENGOT-en29)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Endometrial cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06710847
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With
Mismatch
Repair-
deficient
(
dMMR
) or Microsatellite Instability-High (
MSI
-H) Solid Tumors (
SYLVER
)
WRN inhibitor
Cancer
Colon adenocarcinoma
Endometrial cancer
Rectal adenocarcinoma
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT02628067
Advanced
Phase 2
Active not recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Not yet recruiting (1)
Active not recruiting (1)
Recruitment Country and State
NSW (5)
VIC (5)
QLD (4)
WA (2)
SA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (3)
Phase 2 (1)
Phase 3 (2)
Trial Type
Advanced (7)
Cancer Therapy Class
PD-1
71%
PD-1/PD-L1
71%
WRN
43%
ERBB2
14%
TIGIT
14%
Trop2
14%
IL-2
14%
Facility
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3002 - East Melbourne - Epworth Freemasons (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2500 - Wollongong - Cancer Care Wollongong (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
3199 - Frankston - PASO Medical (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
2109 - North Ryde - Macquarie University Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
Cancer Type
Cancer
Endometrial cancer
Gynaecological cancer
Solid tumour
Colorectal cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Upper gastrointestinal cancer
Gastric cancer
Gastroesophageal cancer
Biomarker-defined solid tumour
Colorectal adenocarcinoma
MSI-H/dMMR solid tumour
dMMR solid cancer
Cervical cancer
Endometrial carcinoma
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Lung cancer
Mesothelioma
Pancreatic cancer
Pancreatobiliary cancer
Respiratory tract cancer
Thoracic cancer
Viral-related cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Colon adenocarcinoma
Rectal adenocarcinoma
Acral lentiginous melanoma
Bladder cancer
Breast adenocarcinoma
Breast cancer
Clear cell renal cell carcinoma
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Exocrine pancreatic cancer
Fallopian tube cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Kidney cancer
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Squamous non-small-cell lung cancer
Triple-negative breast cancer
Urogenital cancer
Anal cancer
Biliary tract cancer
Carcinoma
Cholangiocarcinoma
Endocrine gland cancer
Gastro-entero-pancreatic neuroendocrine tumour
Hepatobiliary cancer
Lung carcinoid tumour
Neuroendocrine carcinoma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Thyroid cancer
Vaginal and vulvar cancer
Vulval cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy